Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature

Table 1

Characteristics of each case of PTLD described, including age at diagnosis, type of SOT, time from SOT to PTLD diagnosis, location of PTLD lesions, immunosuppression, histologic subtype, EBV status, treatment, failure of SOT, and patient status (alive or deceased).

Case	Age at diagnosis (years)	SOT	Time from SOT to PTLD diagnosis (years)	PTLD location	Immunosuppressive regimen	Histologic subtype	EBV status	Treatments	SOT failure	Patient status
1	66	Deceased donor kidney	12	Duodenum	Tacrolimus, mycophenolate mofetil	Burkitt	Negative	ROI, R-EPOCH	No	Alive
2	53	Live donor kidney	7	Stomach, retroperitoneal (RP) lymph nodes (LNs), bone marrow	Tacrolimus, prednisone	RP LN: polymorphic, bone marrow: Hodgkin	Positive	ROI, rituximab, R-GEMOX, AVD	Yes	Alive
3	52	Deceased donor kidney, live donor kidney	30, 16	CNS, oropharynx, lung	Cyclosporine, mycophenolate mofetil, prednisone	Oropharynx: polymorphic, CNS and lung: Hodgkin	Positive	ROI, rituximab, high-dose MTX, brentuximab, high-dose cytarabine	No	Deceased
4	73	Kidney	11	CNS	Mycophenolate mofetil, prednisone	Diffuse large B cell	Positive	Unknown	Unknown	Unknown
5	74	Live donor kidney	10	CNS	Tacrolimus, mycophenolate mofetil, prednisone	Diffuse large B cell	Positive	None	Unknown	Unknown

SOT: solid organ transplantation; PTLD: posttransplant lymphoproliferative disorder; CNS: central nervous system; ROI: reduction of immunosuppression; R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide, adriamycin; R-GEMOX: rituximab, gemcitabine, oxaliplatin; AVD: adriamycin, vinblastine, dacarbazine.